Men with type 2 diabetes are less likely to develop prostate cancer than patients without diabetes. However, the mortality rate is higher. Researchers were able to show that in the affected individuals the androgen receptor and the mitogenic forms of the insulin receptor were more strongly expressed. This could explain why patients with diabetes have a poorer prognosis for prostate cancer.Original Article
You may also like
Ariane de Ganck
Jasper Therapeutics merges with Kira Pharmaceuticals
Lilly to acquire AtaiBeckley in deal worth $2.8bn
Camena Bioscience appoints Gregory McGuinness as CEO
New €25 Million BioReliance Testing Facility Opens...
StockWatch: Lilly’s Up-to-$3.8B Deal for AtaiBeckley...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.
